deltatrials
Completed PHASE1 NCT00000753

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

Sponsor: Glaxo Wellcome

Conditions HIV Infections
Interventions Atevirdine mesylate Didanosine Zalcitabine Zidovudine
Updated 7 times since 2017 Last updated: Oct 27, 2021 Completion: Feb 28, 1995

This PHASE1 trial investigates HIV Infections and is currently completed. Glaxo Wellcome leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glaxo Wellcome
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Upjohn
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Columbus, United States
  • • Los Angeles, United States
  • • Miami, United States
  • • Rochester, United States
  • • St Louis, United States